Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ChromTrace

Financiado

Tracing epigenetic evolution of triple negative breast cancer towards chemo resi...

Tracing epigenetic evolution of triple negative breast cancer towards chemo resistance The emergence of resistance to chemotherapy and targeted therapies is a major challenge for the treatment of cancer. While several genetic mechanisms driving resistance processes have been discovered, non-genetic mechanisms have a... ver más

30/11/2025

CNRS

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-11-09

ERC-2020-STG: ERC STARTING GRANTS

I+D

Cerrada hace 5 años

0% 100% 100%

3 Participantes

CNRS

1.50M€ | Lider

CIBERNOS CONSULTING

162.55K€ | Participante

INSTITUT CURIE FONDATION

216.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-125282OB-I00 USO DE APROXIMACIONES DE CELULA UNICA PARA DECIFRAR LA EPIGE... 472K€ Cerrado

CTQ2010-16638 EVALUACION DE CAMBIOS EPIGENETICOS Y DEL ESTADO REDOX CELULA... 117K€ Cerrado

SC-Plasticity Applying novel single-cell multiomics to elucidate leukaemia... 2M€ Cerrado

SAF2009-08663 CARACTERIZACION EPIGENOMICA DE LAS NEOPLASIAS HEMATOLOGICAS 114K€ Cerrado

RTI2018-094009-B-I00 DETERMINANTES DE LA ESTRUCTURA EPIGENOMICA LATENTE EN CANCER... 182K€ Cerrado

RTI2018-094049-B-I00 DISRUPCION EPIGENETICA Y GENETICA DE LAS MODIFICACIONES DEL... Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2020-11-09
Fecha Fin: 2025-11-30

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto The emergence of resistance to chemotherapy and targeted therapies is a major challenge for the treatment of cancer. While several genetic mechanisms driving resistance processes have been discovered, non-genetic mechanisms have also been shown to contribute to drug resistance. Yet, our restricted understanding of epigenetic evolution has so far limited our ability to modulate resistance using epigenetic modifiers. With ChromTrace, our goal is to reconstruct and define the contribution of epigenetic evolution to chemo-resistance in triple-negative breast tumors. In this aggressive sub-type of breast cancer, chemotherapy is the standard of care, but chemo-resistance remains the major unmet clinical need. We will explore the heterogeneity of H3K27me3chromatin states - key determinant of cell identity - in tumor cells, study how they are transmitted and determine whether they are associated to the resistance phenotype. Combining lineage tracing and targeted sequencing to our original single-cell chromatin profiling approach, we will reconstruct the dynamics of chromatin features over time in the context of genetic evolution. In parallel, using a live-cell microscopy reporter system, we will evaluate the association of recurrent chromatin features with the resistance phenotype and elucidate mechanisms of epigenetic tumor evolution. Our results on the heritability and plasticity of chromatin landscapes will have strong impact on our understanding of epigenetic evolution in cancer. Our long-term goal is to build on this integrated appreciation of molecular tumor evolution processes to propose novel therapeutic strategies to control resistance to chemotherapy. Finally, our approaches being applicable to any dynamic biological system, ChromTrace opens the perspective to study evolution of chromatin landscapes not only in other types of cancer and disease, but also during normal development.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores